摘要
宫颈癌是一种常见的女性恶性肿瘤,目前在我国女性致死癌症中位列第二位,严重威胁广大女性的生命健康。研究表明人乳头瘤病毒(human papillomavirus,HPV)在宫颈癌发病过程中扮演着重要角色,高危型HPV长期感染是诱发宫颈癌的首要因素。宫颈癌临床治疗效果不佳,因此预防和治疗HPV感染显得尤为重要。研究人员已设计出多种不同作用机制的HPV疫苗。类病毒蛋白颗粒(virus-like particles,VLPs)疫苗是目前最为成熟的一种预防用疫苗,已有商业化产品在国外上市,但尚未获得国家食品药品监督管理总局(CFDA)批准进入我国。国内多家科研院所和医药企业正在加紧研发,以期在未来HPV疫苗市场中抢占先机。本文就HPV疫苗研究进展加以综述。
Cervical cancer ranked second cancer death in Chinese women,and became a serious public health problem worldwide to women＇s lives. Studies have shown that human papillomavirus（ HPV） plays an important role in the pathogenesis of cervical cancer. Infection caused by high-risk subtypes of HPV is the primary factor inducing cervical cancer. Because there is no effective therapeutics for cervical cancer,development of HPV vaccine is very important for prevention of HPV infection and prevention of cervical cancer occurring. Variety of HPV vaccines with different forms of HPV oncoprotein antigens and with different molecular mechanisms have been invented by the researcher. virus-like particles（ VLPs） vaccine is the most mature one of preventive vaccines; commercial products have existed in the foreign market but they are not yet approved by CFDA so far. Domestic research institutes and pharmaceutical companies are following footsteps of foreign pharmaceutical leaders,in order to seize the initiative in the future HPV vaccine market. In this paper,we reviewed the current progress in HPV vaccine development.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2015年第20期2369-2375,2400,共8页
Chinese Journal of New Drugs
关键词
宫颈癌
人乳头瘤病毒
疫苗
cervical cancer
human papillomavirus（HPV）
vaccine
